Belzutifan has been approved by the FDA for malignancies linked to von Hippel-Lindau disease

Share This Post

August 2021: Belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, has been approved by the Food and Drug Administration for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET) but do not require immediate surgery.

Belzutifan was studied in 61 patients with VHL-associated RCC (VHL-RCC) diagnosed based on a VHL germline change and at least one detectable solid tumour confined to the kidney in the ongoing Study 004 (NCT03401788), an open-label clinical investigation. Patients with other VHL-related malignancies, such as CNS hemangioblastomas and pNET, were enrolled. Belzutifan 120 mg was given to patients once a day until disease progression or intolerable toxicity.

The overall response rate (ORR) was the primary efficacy endpoint, as defined by radiological assessment and assessed by an independent review committee using RECIST v1.1. The duration of response (DoR) and time to response were two other efficacy goals (TTR). In individuals with VHL-associated RCC, an ORR of 49% (95 percent CI: 36, 62) was found. All patients with VHL-RCC who had a response were tracked for at least 18 months after treatment began. The median DoR was not met; 56% of respondents had a DoR of less than 12 months and an average TTR of 8 months. 24 patients with measurable CNS hemangioblastomas had an ORR of 63 percent, and 12 patients with measurable pNET had an ORR of 83 percent in patients with other VHL-associated non-RCC malignancies. For CNS hemangioblastomas and pNET, the median DoR was not met, with response durations of less than 12 months in 73 percent and 50 percent of patients, respectively.

Reduced haemoglobin, anaemia, fatigue, increased creatinine, headache, dizziness, elevated hyperglycemia, and nausea were the most prevalent adverse effects, including laboratory abnormalities, reported in almost 20% of patients who took belzutifan. Belzutifan usage can cause severe anaemia and hypoxia. Anemia was seen in 90% of participants in Study 004, with 7% having Grade 3 anaemia. Patients should be transfused as needed by their doctors. In individuals on belzutifan, the use of erythropoiesis stimulating drugs to treat anaemia is not suggested. Hypoxia occurred in 1.6 percent of patients in Study 004. Belzutifan can make some hormonal contraceptives ineffective, and it can harm an embryo or foetus if taken during pregnancy.

Belzutifan should be taken once a day, with or without food, in a dosage of 120 mg.

 

Reference: https://www.fda.gov/

Check details here.

Take second opinion on renal cell carcinoma


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy